Una lectura de la Llei 10/2001, de 13 de juliol, d'arxius i documents

S'analitza el procés d'elaboració de la nova Llei d'arxius destacant les principals modificacions que recull el text definitiu en relació al projecte. Es comenten també els punts més destacats de la Llei al voltant de tres eixos principals: la definició del Sistema d'Arxius de Catalunya, el sistema de gestió documental i l'accés als documents del patrimoni documental català.

Iowa Workforce Monthly, February 2010, Issue 13

Highlights: * Iowa’s Unemployment Insurance Tax Bureau is getting a new online filing system, called My Iowa UI.............pg. 2 * Disability Navigator Jade Hunt sent us this success story..........................pg. 2 * Frank Nucaro attended Re-Employment Services (RES) training in December and the Skills Development lab in January...........................................pg. 2

Rapid identification of malaria vaccine candidates based on alpha-helical coiled coil protein motif.

To identify malaria antigens for vaccine development, we selected alpha-helical coiled coil domains of proteins predicted to be present in the parasite erythrocytic stage. The corresponding synthetic peptides are expected to mimic structurally "native" epitopes. Indeed the 95 chemically synthesized peptides were all specifically recognized by human immune sera, though at various prevalence. Peptide specific antibodies were obtained both by affinity-purification from malaria immune sera and by immunization of mice. These antibodies did not show significant cross reactions, i.e., they were specific for the original peptide, reacted with native parasite proteins in infected erythrocytes and several were active in inhibiting in vitro parasite growth. Circular dichroism studies indicated that the selected peptides assumed partial or high alpha-helical content. Thus, we demonstrate that the bioinformatics/chemical synthesis approach described here can lead to the rapid identification of molecules which target biologically active antibodies, thus identifying suitable vaccine candidates. This strategy can be, in principle, extended to vaccine discovery in a wide range of other pathogens.

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Although increasing evidence suggests that CTL are important to fight the development of some cancers, the frequency of detectable tumor-specific T cells is low in cancer patients, and these cells have generally poor functional capacities, compared with virus-specific CD8(+) T cells. The generation with a vaccine of potent CTL responses against tumor Ags therefore remains a major challenge. In the present study, ex vivo analyses of Melan-A-specific CD8(+) T cells following vaccination with Melan-A peptide and CpG oligodeoxynucleotides revealed the successful induction in the circulation of effective melanoma-specific T cells, i.e., with phenotypic and functional characteristics similar to those of CTL specific for immunodominant viral Ags. Nonetheless, the eventual impact on tumor development in vaccinated melanoma donors remained limited. The comprehensive study of vaccinated patient metastasis shows that vaccine-driven tumor-infiltrating lymphocytes, although activated, still differed in functional capacities compared with blood counterparts. This coincided with a significant increase of FoxP3(+) regulatory T cell activity within the tumor. The consistent induction of effective tumor-specific CD8(+) T cells in the circulation with a vaccine represents a major achievement; however, clinical benefit may not be achieved unless the tumor environment can be altered to enable CD8(+) T cell efficacy.

A vaccine against nicotine for smoking cessation: a randomized controlled trial.

BACKGROUND: Tobacco dependence is the leading cause of preventable death and disabilities worldwide and nicotine is the main substance responsible for the addiction to tobacco. A vaccine against nicotine was tested in a 6-month randomized, double blind phase II smoking cessation study in 341 smokers with a subsequent 6-month follow-up period. METHODOLOGY/PRINCIPAL FINDINGS: 229 subjects were randomized to receive five intramuscular injections of the nicotine vaccine and 112 to receive placebo at monthly intervals. All subjects received individual behavioral smoking cessation counseling. The vaccine was safe, generally well tolerated and highly immunogenic, inducing a 100% antibody responder rate after the first injection. Point prevalence of abstinence at month 2 showed a statistically significant difference between subjects treated with Nicotine-Qbeta (47.2%) and placebo (35.1%) (P = 0.036), but continuous abstinence between months 2 and 6 was not significantly different. However, in subgroup analysis of the per-protocol population, the third of subjects with highest antibody levels showed higher continuous abstinence from month 2 until month 6 (56.6%) than placebo treated participants (31.3%) (OR 2.9; P = 0.004) while medium and low antibody levels did not increase abstinence rates. After 12 month, the difference in continuous abstinence rate between subjects on placebo and those with high antibody response was maintained (difference 20.2%, P = 0.012). CONCLUSIONS: Whereas Nicotine-Qbeta did not significantly increase continuous abstinence rates in the intention-to-treat population, subgroup analyses of the per-protocol population suggest that such a vaccination against nicotine can significantly increase continuous abstinence rates in smokers when sufficiently high antibody levels are achieved. Immunotherapy might open a new avenue to the treatment of nicotine addiction. TRIAL REGISTRATION: Swiss Medical Registry 2003DR2327; ClinicalTrials.gov NCT00369616.

Infonet, March 13, 2009, Issue 5

A publication of the Governorʼs DD Council & ID Action. It was first created nearly two decades ago as a print-only publication, sent to a few hundred people. Today we offer our nearly 3,000 direct subscribers and a variety of services.

Infonet, February 13, 2009, Issue 3

A publication of the Governorʼs DD Council & ID Action. It was first created nearly two decades ago as a print-only publication, sent to a few hundred people. Today we offer our nearly 3,000 direct subscribers and a variety of services.

Informe sobre la Jornada de presentació de la Llei 10/2001, de 13 de juliol, d'arxius i documents (Escola d'Administració Pública de Catalunya. Barcelona, 17 de gener de 2002)

El 17 de gener de 2002, l'Escola d'Administració Pública de Catalunya, el Servei d'Arxius de la Direcció General de Patrimoni Cultural de la Generalitat de Catalunya i l'Associació d'Arxivers de Catalunya (AAC) van organitzar una jornada de divulgació, reflexió i debat sobre la Llei 10/2002, de 13 de juliol, d'arxius i documents. L'objectiu de la Jornada era donar a conèixer als professionals dels arxius aquesta llei i es va centrar a analitzar-ne l'abast, la incidència i les implicacions més rellevants. Emmarcada en la línia de la formació interdepartamental de l'Escola d'Administració Pública de Catalunya, la Jornada tenia com a destinataris els arxivers de l'Administració de la Generalitat de Catalunya, de l'Administració local i d'altres institucions públiques.